|
Newsletter
|
Cancer Drug News published by Espicom Business Intelligence. This newsletter price starts from US $ 1080.
|
Monitoring business developments in world anticancer drug markets is becoming more and more vital as cancer, in all its guises, remains one of the most resistant conditions, and its position in the pharmaceutical industry is assured.
In an effort to stay in touch with the companies, products, alliances and research that are shaping the global cancer market, Espicom has launched this major new publication.
Cancer Drug News (CDN) can save you the time and effort of ensuring you have the necessary information to keep up-to-date with the developments in this world market. Incorporating primary resource material augmented with data from Espicom's unique intelligence base, CDN provides a compelling, easy-to-read route to complete market knowledge.
|
The following sections appear in every issue:
- Therapies for Cancer-Related Complications
- General Development News
- Conference Listings
A selection of the following topics will appear each month, depending on news availability:
- Breast Cancer
- Haematological Cancers
- Liver Cancer
- Gastro-Intestinal Cancers
- Lung Cancer
- Gynaecological Cancers
- Genito-Urinary Cancers
- Brain Tumours
- Head and Neck Cancers
- Melanoma/Sarcoma
|
